Celmatix Appoints Women’s Health Pioneer Dr. Bart CJM Fauser to Chairmanship of Scientific Advisory Board and Newly Formed Clinical Trial Steering Committee

·3 min read

Fauser appointment builds on continued progress of lead AMHR2 agonist program.

  • Celmatix lead AMHR2 agonist compound achieves in vivo PK/PD milestone.

  • Dr. Fauser, one of the most cited investigators in reproductive health, brings deep expertise in ovarian stimulation and pathophysiology of ovarian function to Celmatix advisory board and trial committee.

  • One of the first to hypothesize a role for Anti-Mullerian Hormone in regulating ovarian reserve over 20 years ago, Dr. Fauser will play a key role in accelerating the company’s lead AMHR2 agonist program toward first-in-human trials.

NEW YORK, July 05, 2022--(BUSINESS WIRE)--Celmatix Inc., the leading women’s health biotech focused on ovarian biology, today announced that Reproductive Endocrinology pioneer Dr. Bart CJM Fauser, MD, PhD, FRCOG, will join and Chair its Scientific Advisory Board and newly-formed Clinical Trial Steering Committee. This update follows the company’s recent announcement of the identification of a novel AMHR2 agonist compound that has demonstrated robust biological activity in multiple therapeutically relevant preclinical assays and a pharmacokinetic profile consistent with the desired product profile for an injectable drug. Additionally, the company announced today that the same novel compound has also achieved an important in vivo PK/PD milestone and demonstrates therapeutically-relevant ovarian responses in a rodent model.

Dr. Fauser, a pioneer in ovarian physiology and function, has published over 500 peer reviewed articles, including one in which he and co-authors were the first to propose Anti-Mullerian Hormone (AMH) as a regulator of ovarian reserve. He is a Professor Emeritus of Reproductive Medicine, Gynecologist, former Chair of the Department for Reproductive Medicine and Gynecology and Head of the Division of Woman & Baby at the University of Utrecht and the University Medical Center Utrecht, The Netherlands.

He is also a Fellow ad Eundum of the Royal College of Obstetrics and Gynaecology (RCOG), Honorary member of European Society of Human Reproduction and Embryology (ESHRE), Scientific Director of the International Federation of Fertility Societies (IFFS), international member of the National Academy of Medicine (US), Editor-in-Chief of Reproductive Biomedicine Online (RBMO), Editor of Fertility & Sterility Science, and Knight of the Order of the Netherlands Lion. Dr. Fauser also previously acted as a member of the board of the Dutch Medical Research Counsel (ZonMW), Editor-in-Chief of Human Reproduction Update, chair of the World Health Organization (WHO) steering committee for infertility guidelines, Chair of the ESHRE SIG Reproductive Endocrinology, Fulbright postdoctoral scholar at the University of California, San Diego, Professor and Division Director at the Erasmus University, Rotterdam (The Netherlands); and acted as visiting professor at Stanford University School of Medicine (California, USA), Free University of Brussels (Belgium), University of Siena (Italy), University of Southampton (UK), and the University of Adelaide (Australia).

Dr. Piraye Yurttas Beim, Celmatix Founder and CEO commented, "We are delighted to see continued progress for our lead AMHR2 compound, which recently achieved a PK/PD milestone consistent with our desired product profile for an injectable drug. As our preclinical development matures, we are proud to partner with Dr. Bart Fauser in assembling a strong bench of clinicians to guide preparations for our first human trials. There are few investigators who have singularly made the impact that Dr. Fauser has on our understanding of ovarian stimulation and function. Accordingly, he is the ideal Chair for our new Clinical Trial Steering Committee."

Dr. Fauser commented, "Therapeutic modulation of the AMH receptor will unlock huge opportunities in women’s health. Celmatix was a pioneer in understanding the importance of AMH as an ovarian biomarker and is now leading the field in making AMH therapeutics a reality. I look forward to working with Dr. Beim and the Celmatix team to support the translation of their ongoing scientific achievements into the clinic."

About Celmatix

Celmatix Inc. is a preclinical-stage women’s health biotech focused uniquely on ovarian biology. With a lead "pipeline-in-a-pill" AMHR2 agonist program focused on ovarian senescence, and collaborations with industry leaders, Celmatix is addressing areas of high unmet need by developing the next generation of interventions and pioneering advancements in ovarian health. Celmatix’s proprietary multi-omic ovarian health platform, the world’s largest of its kind, is the foundation of the company’s novel pipeline of first-in-class therapies. For more information, visit the company’s website at www.celmatix.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20220705005620/en/

Contacts

Media
Jamie Kinder, MWW
jkinder@mww.com

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting